Key facts
- It has raised $20.0M; the latest was Secondary Transaction - Private in Mar 2025.
- Notable investors include Changxing Fund, 3E Bioventures Capital, Peak Valley Capital, Yongjin Group, Binhai Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ITabMed
- ·The full record, as it builds
Funding rounds
No funding rounds for ITabMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ITabMed
Developer of immunotherapy drugs for treatment of cancer. The company's immunotherapy antibody technology platform has produced two products, A-319 and A-337, that have entered clinical phase I studies, and there are multiple candidate drug molecules in different preclinical development stages.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- itabmed.com/
- Ownership
- Privately Held (backing)
ITabMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ITabMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ITabMed in its N-PORT filings yet. We sweep new filings monthly.